CSL H1N1 Pandemic Influenza Vaccine

The CSL H1N1 Pandemic Influenza Vaccine (CSL425) is a monovalent, inactivated, split-virion vaccine developed by CSL Limited to prevent infection caused by the 2009 pandemic influenza A (H1N1) virus. The vaccine contains hemagglutinin (HA) antigens derived from the A/California/07/2009 (H1N1)-like virus strain. It functions by stimulating the immune system to produce neutralizing antibodies against the viral hemagglutinin surface protein, thereby preventing the virus from attaching to and entering host cells. Evaluated in Phase II clinical trials, including pediatric studies in children aged 6 months to 9 years, the vaccine was produced in both thimerosal-containing and thimerosal-free formulations for intramuscular administration. It was authorized for use in several countries, including Australia, during the 2009 pandemic.

Brand names

Panvax

Other names

CSL H1N1 Pandemic Influenza Vaccine2009 H1N1 Influenza Vaccinemonovalent inactivated split-virion H1N1 vaccine